A clinical research study to find out if the drug dabrafenib is safe and to determine how dabrafenib is metabolized (broken down in the body) by people who have varying degrees of renal impairment (a condition in which the kidneys are not working as well as they normally should) compared with people who do not have renal impairment.
You will remain at the clinic for 6 consecutive days starting from the day before you take the study drug (Day -1 to Day 5). After all procedures are completed on Day 5, you will be discharged from the study site.
Inclusion Criteria:
Must be Male and/or female subjects 18-75 years of age
Body mass index (BMI) between ≥18.0 and ≤38.0 kg/m2, with body weight ≥110 lbsg and
no more than 300 lbs
An absolute GFR ≥ 90 mL/min
If on diaysis must be stable enough to skip 1 dialysis treatment.